CoChat
Sign Up
Cited by 569Extracellular vesicles in diseaseCellular transport and secretionNanoparticle-Based Drug Delivery

Extracellular vesicles in physiological and pathological conditions

Open access
Yuana, Yuana, Sturk, Auguste, Nieuwland, Rienk·2013·Blood Reviews
DOI 10.1016/j.blre.2012.12.002
Open this paper in CoChat — free accountOpen PDF

Abstract

Body fluids contain surprising numbers of cell-derived vesicles which are now thought to contribute to both physiology and pathology. Tools to improve the detection of vesicles are being developed and clinical applications using vesicles for diagnosis, prognosis, and therapy are under investigation. The increased understanding why cells release vesicles, how vesicles play a role in intercellular communication, and how vesicles may concurrently contribute to cellular homeostasis and host defense, reveals a very complex and sophisticated contribution of vesicles to health and disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.blre.2012.12.002

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Extracellular vesicles are membrane fragments shed from cell surfaces to transfer cytoplasmic or membrane contents to neighboring cells or body fluids.

    “Extracellular vesicles (Evs) are membrane fragments shed from cell surfaces to transfer cytoplasmic or membrane contents to neighboring cells or body fluids.”

    From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [6]

    The Introduction and Practice points (pages not provided) describe membrane-enclosed EVs that carry biomolecules to recipient cells, and the Introduction reports EVs in body fluids. But the Formation and shedding section distinguishes microvesicles shed directly from the cell surface from exosomes released through multivesicular bodies; it does not characterize all EVs as surface-shed fragments. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 138

  1. Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, et al. Gram-positive bacteria pro- duce membrane vesicles: proteomics-based characterization of Staphylococcus aureus-derived membrane vesicles. Proteomics 2009;9(24):5425-36.
  2. Deatherage BL, Cookson BT. Membrane vesicle release in bacteria, eukaryotes, and archaea: a conserved yet underappreciated aspect of microbial life. Infect Immun 2012;80(6):1948-57.
  3. Van Der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012;64(3): 676-705.
  4. Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 2011;68(16):2667-88.
  5. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89(4):1121-32.
  6. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and func- tion. Nat Rev Immunol 2002;2(8):569-79.
  7. Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis 2006;36(2):182-7.
  8. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62(9):971-88.
  9. Frey B, Gaipl US. The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. Semin Immunopathol 2011;33(5):497-516.
  10. Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, et al. Abnor- mal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005;4(10): 1595-604.
  11. Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small mol- ecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res 2003;63(15):4331-7.
  12. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics 2010;73(10):1907-20.
  13. Tesselaar ME, Romijn FP, van der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombo- sis? J Thromb Haemost 2007;5(3):520-7.
  14. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009;15(22):6830-40.
  15. Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, et al. Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation. Ann Hematol 2008;87(6):451-7.
  16. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003;59(2):277-87.
  17. Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 2010;8(11):2358-68.
  18. Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FP, Kraan MC, et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints sup- port coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002;46(11):2857-66.
  19. Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar MA. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002;46(6):1498-503.
  20. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999;94(11):3791-9.
  21. Van Der Pol E, Hoekstra AG, Sturk A, Otto C, Van Leeuwen TG, Nieuwland R. Op- tical and non-optical methods for detection and characterization of microparti- cles and exosomes. J Thromb Haemost 2010;8(12):2596-607.
  22. Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, et al. Induction of microparticle-and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004;103(12):4545-53.
  23. Salzer U, Hinterdorfer P, Hunger U, Borken C, Prohaska R. Ca(++)-dependent vesicle release from erythrocytes involves stomatin-specific lipid rafts, synexin (annexin VII), and sorcin. Blood 2002;99(7):2569-77.
  24. Del CI, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005;106(5):1604-11.
  25. Salzer U, Zhu R, Luten M, Isobe H, Pastushenko V, Perkmann T, et al. Vesicles gen- erated during storage of red cells are rich in the lipid raft marker stomatin. Transfusion 2008;48(3):451-62.
  26. Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure chests for prostate cancer. Eur Urol 2011;59(5):823-31.
  27. Bernimoulin M, Waters EK, Foy M, Steele BM, Sullivan M, Falet H, et al. Differential stimulation of monocytic cells results in distinct populations of microparticles. J Thromb Haemost 2009;7(6):1019-28.
  28. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003;109(4):175-80.
  29. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006;66(18):9290-8.
  30. Skog J, Wurdinger T, van RS, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblas- toma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470-6.
  31. Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007;21(3):157-71.
  32. Satta N, Toti F, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome: an inherited defect of the procoagulant activity of platelets. Platelets 1997;8(2-3):117-24.
  33. Connor DE, Exner T, Ma DD, Joseph JE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 2010;103(5):1044-52.
  34. Perez-Pujol S, Marker PH, Key NS. Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer. Cytometry A 2007;71(1):38-45.
  35. Ayers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M, et al. Measure- ment of circulating cell-derived microparticles by flow cytometry: sources of variability within the assay. Thromb Res 2011;127(4):370-7.
  36. Pant S, Hilton H, Burczynski ME. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012;83(11):1484-94.
  37. Record M, Subra C, Silvente-Poirot S, Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol 2011;81(10): 1171-82.
  38. Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? Front Physiol 2012;3:124.
  39. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008;319(5867):1244-7.
  40. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune re- sponses. Nat Rev Immunol 2009;9(8):581-93.
  41. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer- associated immunosuppressive microenvironments. Semin Immunopathol 2011;33(5):441-54.
  42. Savina A, Furlan M, Vidal M, Colombo MI. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J Biol Chem 2003;278(22): 20083-90.
  43. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009;101(3):439-51.
  44. Lasser C, Alikhani VS, Ekstrom K, Eldh M, Paredes PT, Bossios A, et al. Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl Med 2011;9:9.
  45. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic poten- tials. Biochim Biophys Acta 2012;1820(7):940-8.
  46. Keller S, Rupp C, Stoeck A, Runz S, Fogel M, Lugert S, et al. CD24 is a marker of exosomes secreted into urine and amniotic fluid. Kidney Int 2007;72(9): 1095-102.
  47. Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A 2004;101(36):13368-73.
  48. Miranda KC, Bond DT, McKee M, Skog J, Paunescu TG, Da SN, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal dis- ease. Kidney Int 2010;78(2):191-9.
  49. Berckmans RJ, Sturk A, van Tienen LM, Schaap MC, Nieuwland R. Cell-derived vesicles exposing coagulant tissue factor in saliva. Blood 2011;117(11):3172-80.
  50. Street JM, Barran PE, Mackay CL, Weidt S, Balmforth C, Walsh TS, et al. Identification and proteomic profiling of exosomes in human cerebrospinal fluid. J Transl Med 2012;10:5.
  51. Turola E, Furlan R, Bianco F, Matteoli M, Verderio C. Microglial microvesicle se- cretion and intercellular signaling. Front Physiol 2012;3:149.
  52. Berckmans RJ, Nieuwland R, Kraan MC, Schaap MC, Pots D, Smeets TJ, et al. Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther 2005;7(3):R536-44.
  53. Zhang HG, Liu C, Su K, Yu S, Zhang L, Zhang S, et al. A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death. J Immunol 2006;176(12):7385-93.
  54. Yang C, Mwaikambo BR, Zhu T, Gagnon C, Lafleur J, Seshadri S, et al. Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negative- ly regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol 2008;294(2):R467-76.
  55. Mostefai HA, Andriantsitohaina R, Martinez MC. Plasma membrane microparticles in angiogenesis: role in ischemic diseases and in cancer. Physiol Res 2008;57(3): 311-20.
  56. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angio- genesis in vitro. Br J Haematol 2004;124(3):376-84.
  57. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles in- duce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005;67(1):30-8.
  58. Boulanger CM, Tedgui A. Dying for attention: microparticles and angiogenesis. Cardiovasc Res 2005;67(1):1-3.
  59. Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene 2012;31(36):4054-66.
  60. Bussolati B, Grange C, Camussi G. Tumor exploits alternative strategies to achieve vascularization. FASEB J 2011;25(9):2874-82.
  61. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002;160(2): 673-80.
  62. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005;113(5):752-60.
  63. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006;107(5):1761-7.
  64. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. En- hancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006;46(7):1199-209.
  65. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012;18(6):883-91.
  66. Nilsson RJ, Balaj L, Hulleman E, van RS, Pegtel DM, Walraven M, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011;118(13):3680-3.
  67. Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, et al. New mecha- nism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 2010;116(13):2385-94.
  68. Tatischeff I. Cell-derived microvesicles and antitumoral multidrug resistance. C R Biol 2012;335(2):103-6.
  69. Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membrane micro- particles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009;23(9):1643-9.
  70. Bruno S, Grange C, Collino F, Deregibus MC, Cantaluppi V, Biancone L, et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One 2012;7(3):e33115.
  71. Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327(5965):580-3.
  72. Mause SF, von HP, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005;25(7):1512-8.
  73. Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils dissemi- nate anti-inflammatory microparticles by ectocytosis. Blood 2004;104(8): 2543-8.
  74. Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M. Annexin 1 medi- ates the rapid anti-inflammatory effects of neutrophil-derived microparticles. Blood 2008;112(6):2512-9.
  75. Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet- mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood 2008;111(10):5028-36.
  76. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL. Tumor-derived microvesicles promote regulatory T cell expansion and induce apo- ptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009;183(6): 3720-30.
  77. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006;26(3): 456-61.
  78. Simak J, Holada K, Vostal JG. Release of annexin V-binding membrane micropar- ticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. BMC Cell Biol 2002;3:11.
  79. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, gnat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor- dependent procoagulant activity. Blood 2002;99(11):3962-70.
  80. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. Plasminogen activa- tor inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 2002;106(18):2372-8.
  81. Yuana Y, Osanto S, Bertina RM. Use of immuno-magnetic beads for direct capture of nanosized microparticles from plasma. Blood Coagul Fibrinolysis 2012;23(3): 244-50.
  82. Henriksson CE, Klingenberg O, Ovstebo R, Joo GB, Westvik AB, Kierulf P. Dis- crepancy between tissue factor activity and tissue factor expression in endotoxin-induced monocytes is associated with apoptosis and necrosis. Thromb Haemost 2005;94(6):1236-44.
  83. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999;96(5): 2311-5.
  84. Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation. Which? Where? When? Arterioscler Thromb Vasc Biol 2009;29(12):1989-96.
  85. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin gener- ation. Thromb Haemost 2001;85(4):639-46.
  86. Butenas S, Mann KG. Active tissue factor in blood? Nat Med 2004;10(11): 1155-6.
  87. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem 2007;282(35): 25416-24.
  88. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, et al. Cell-derived microparticles generated in patients during cardio- pulmonary bypass are highly procoagulant. Circulation 1997;96(10):3534-41.
  89. Biro E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, et al. Human cell-derived microparticles promote thrombus formation in vivo in a tis- sue factor-dependent manner. J Thromb Haemost 2003;1(12):2561-8.
  90. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and mono- cytes. Blood 2003;102(7):2678-83.
  91. van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF, et al. Circulating erythrocyte-derived microparticles are associated with coagu- lation activation in sickle cell disease. Haematologica 2009;94(11):1513-9.
  92. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circula- tion 2000;101(8):841-3.
  93. Morel O, Jesel L, Freyssinet JM, Toti F. Elevated levels of procoagulant micropar- ticles in a patient with myocardial infarction, antiphospholipid antibodies and multifocal cardiac thrombosis. Thromb J 2005;3:15.
  94. Trappenburg MC, van SM, Marchetti M, Spronk HM, ten CH, Leyte A, et al. Elevat- ed procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009;94(7):911-8.
  95. Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle- associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost 2009;7(8):1421-3.
  96. Darbousset R, Thomas GM, Mezouar S, Frere C, Bonier R, Mackman N, et al. Tissue factor-positive neutrophils bind to injured endothelial wall and initiate thrombus formation. Blood 2012;120(10):2133-43.
  97. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor- bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 2008;6(9):1517-24.
  98. van den Goor J, Saxby B, Tijssen J, Wesnes K, de MB, Nieuwland R. Improvement of cognitive test performance in patients undergoing primary CABG and other CPB-assisted cardiac procedures. Perfusion 2008;23(5):267-73.
  99. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P, et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006;55(7):808-18.
  100. Baj-Krzyworzeka M, Baran J, Weglarczyk K, Szatanek R, Szaflarska A, Siedlar M, et al. Tumour-derived microvesicles (TMV) mimic the effect of tumour cells on monocyte subpopulations. Anticancer Res 2010;30(9):3515-9.
  101. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41(7):1241-50.
  102. Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA. Tumor- derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett 2009;283(2):168-75.
  103. Boing AN, Hau CM, Sturk A, Nieuwland R. Platelet microparticles contain active caspase 3. Platelets 2008;19(2):96-103.
  104. Tait JF, Smith C. Phosphatidylserine receptors: role of CD36 in binding of anionic phospholipid vesicles to monocytic cells. J Biol Chem 1999;274(5):3048-54.
  105. Chironi G, Simon A, Hugel B, Del PM, Gariepy J, Freyssinet JM, et al. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006;26(12):2775-80.
  106. Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R, et al. Plasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. J Atheroscler Thromb 2010;17(4):342-9.
  107. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Signifi- cance of a multiple biomarkers strategy including endothelial dysfunction to im- prove risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009;54(7):601-8.
  108. Janowska-Wieczorek A, Majka M, Kijowski J, Baj-Krzyworzeka M, Reca R, Turner AR, et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001;98(10):3143-9.
  109. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol 2012;3:359.
  110. Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al. Mesen- chymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009;20(5):1053-67.
  111. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes de- rived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 2005;174(10):6440-8.
  112. Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, et al. Dendritic cell derived-exosomes: biology and clinical implementations. J Leukoc Biol 2006;80(3): 471-8.
  113. Le Pecq JB. Dexosomes as a therapeutic cancer vaccine: from bench to bedside. Blood Cells Mol Dis 2005;35(2):129-35.
  114. Altieri SL, Khan AN, Tomasi TB. Exosomes from plasmacytoma cells as a tumor vaccine. J Immunother 2004;27(4):282-8.
  115. Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost 2011;105(3):396-408.
  116. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, et al. Produc- tion and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002;270(2):211-26.
  117. Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces effi- cient antitumor immune responses. Cancer Res 2008;68(4):1228-35.
  118. Van Der Pol E, van Gemert MJ, Sturk A, Nieuwland R, Van Leeuwen TG. Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost 2012;10(5):919-30.
  119. Tait JF, Gibson D. Phospholipid binding of annexin V: effects of calcium and membrane phosphatidylserine content. Arch Biochem Biophys 1992;298(1): 187-91.
  120. Shi J, Heegaard CW, Rasmussen JT, Gilbert GE. Lactadherin binds selectively to membranes containing phosphatidyl-L-serine and increased curvature. Biochim Biophys Acta 2004;1667(1):82-90.
  121. Nomura S, Shouzu A, Taomoto K, Togane Y, Goto S, Ozaki Y, et al. Assessment of an ELISA kit for platelet-derived microparticles by joint research at many insti- tutes in Japan. J Atheroscler Thromb 2009;16(6):878-87.
  122. Yuana Y, Oosterkamp TH, Bahatyrova S, Ashcroft B, Garcia RP, Bertina RM, et al. Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost 2010;8(2):315-23.
  123. Siedlecki CA, Wang IW, Higashi JM, Kottke-Marchant K, Marchant RE. Platelet-derived microparticles on synthetic surfaces observed by atomic force microscopy and fluorescence microscopy. Biomaterials 1999;20(16): 1521-9.
  124. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer pa- tients. Cancer Immunol Immunother 2010;59(6):841-50.
  125. Gyorgy B, Modos K, Pallinger E, Paloczi K, Pasztoi M, Misjak P, et al. Detection and isolation of cell-derived microparticles are compromised by protein com- plexes resulting from shared biophysical parameters. Blood 2011;117(4): e39-48.
  126. Soo CY, Song Y, Zheng Y, Campbell EC, Riches AC, Gunn-Moore F, et al. Nanopar- ticle tracking analysis monitors microvesicle and exosome secretion from im- mune cells. Immunology 2012;136(2):192-7.
  127. Gercel-Taylor C, Atay S, Tullis RH, Kesimer M, Taylor DD. Nanoparticle analysis of circulating cell-derived vesicles in ovarian cancer patients. Anal Biochem 2012;428(1):44-53.
  128. Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggre- gates. Pharm Res 2010;27(5):796-810.
  129. Dragovic RA, Gardiner C, Brooks AS, Tannetta DS, Ferguson DJ, Hole P, et al. Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis. Nanomedicine 2011;7(6):780-8.
  130. Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP, et al. Review: does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta 2012;33(Suppl.):S48-54.
  131. Sharma S, Rasool HI, Palanisamy V, Mathisen C, Schmidt M, Wong DT, et al. Structural-mechanical characterization of nanoparticle exosomes in human saliva, using correlative AFM, FESEM, and force spectroscopy. ACS Nano 2010;4(4): 1921-6.
  132. Ashcroft BA, de SJ, Yuana Y, Osanto S, Bertina R, Kuil ME. Determination of the size distribution of blood microparticles directly in plasma using atomic force microscopy and microfluidics. Biomed Microdevices 2012;14(4):641-9.
  133. van der Vlist EJ, Nolte-'t Hoen EN, Stoorvogel W, Arkesteijn GJ, Wauben MH. Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry. Nat Protoc 2012;7(7):1311-26.
  134. Hoen EN, van der Vlist EJ, Aalberts M, Mertens HC, Bosch BJ, Bartelink W, et al. Quantitative and qualitative flow cytometric analysis of nanosized cell-derived membrane vesicles. Nanomedicine 2012;8(5):712-20.
  135. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967;13(3):269-88.
  136. Denzer K, van EM, Kleijmeer MJ, Jakobson E, de GC, Geuze HJ. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 2000;165(3):1259-65.
  137. Turiak L, Misjak P, Szabo TG, Aradi B, Paloczi K, Ozohanics O, et al. Proteomic characterization of thymocyte-derived microvesicles and apoptotic bodies in BALB/c mice. J Proteomics 2011;74(10):2025-33.
  138. Zomer A, Vendrig T, Hopmans ES, van EM, Middeldorp JM, Pegtel DM. Exosomes: fit to deliver small RNA. Commun Integr Biol 2010;3(5):447-50.

Cited by

Sorted by citations

Authors
Yuana, Y., Sturk, A., & Nieuwland, R.
Affiliations
Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Nieuwland, Rienk
ORCID
Nieuwland, Rienk
Venue
Blood Reviews
Publisher
Elsevier BV
Published
2013-01
Volume
27
Issue
1
Pages
31-39
ISSN
0268-960X (ISSN-L)
DOI
10.1016/j.blre.2012.12.002
OpenAlex
W2081128658
Cited by
569
References
3
Citations by year
2026: 35 · 2025: 39 · 2024: 57 · 2023: 51 · 2022: 61 · 2021: 78 · 2020: 55 · 2019: 53 · 2018: 46 · 2017: 23 · 2016: 32 · 2015: 22 · 2014: 12 · 2013: 3
FWCI
1.08
Type
journal article
Language
en
Open access
Licence
Locations
  • Blood Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
extracellular vesicles, cell-derived vesicles, intercellular communication, vesicle detection, host defense, cellular homeostasis
MeSH terms
Blood Coagulation, Body Fluids, Cell Communication, Cell Survival, Cytosol, Exocytosis, Extracellular Space, Homeostasis, Humans, Inflammation, Lymphocytes, Neovascularization, Physiologic, Endothelial Cells, Exosomes, Multivesicular Bodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review